Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Tozinameran

Macrophage activating syndrome: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Simpson J, et al. A Case of a Relapsing Remitting Macrophage Activating Syndrome After Covid-19 Vaccine In a Teenager with UNC13D Heterozygous Variant of Uncertain Significance. Clinical Immunology 250 (Suppl.): abstr. 39, May 2023. Available from: URL: http://doi.org/10.1016/j.clim.2023.109386 [abstract] Simpson J, et al. A Case of a Relapsing Remitting Macrophage Activating Syndrome After Covid-19 Vaccine In a Teenager with UNC13D Heterozygous Variant of Uncertain Significance. Clinical Immunology 250 (Suppl.): abstr. 39, May 2023. Available from: URL: http://​doi.​org/​10.​1016/​j.​clim.​2023.​109386 [abstract]
Metadaten
Titel
Tozinameran
Macrophage activating syndrome: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41653-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Tofacitinib

Case report

Aciclovir